secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001048477-22-000020
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin appoints Erin Burkhart as Chief Accounting Officer
-----------------------------------------------------------

- Burkhart named Group VP, CAO effective May 2, 2022; succeeds Brian Mueller who remains CFO and principal financial officer.
- Burkhart joins from Eli Lilly where she held senior roles; CPA with public accounting background at Arthur Andersen and Deloitte.
- Compensation includes $400K salary, 45% cash incentive target, $250K sign-on bonus, $250K relocation bonus, and $1.5M equity awards (RSUs + options).
- Equity grants under 2017 Equity Incentive Plan; RSUs vest 25% annually, options vest monthly over 4 years with 1-year cliff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847722000020/0001048477-22-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847722000020/bmrn-20220505.htm
  HTML page:      https://secwatch.observer/filing/0001048477-22-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer